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“I had every [indication] of pre-eclampsia except for proteinuria until 38 weeks. When I finally presented 
with +4 protein, my BP was 198/130 and I had gained 50 lbs of water in 6 weeks.”
Jenn P
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PHYSIOLOGICAL CHANGES OF 
PROTEINURIA IN PREGNANCY
During normal pregnancy, proteinuria increases 
through the trimesters, from 0.15 g/d outside 
pregnancy to 0.3 g/d during pregnancy. This is 
attributable to the increase in renal plasma flow and 
glomerular filtration rate, as well as changes in 
protein handling in the nephron; these changes 
resolve after pregnancy1.
The proteinuria of pregnancy consists of both 
glomerular and tubular proteins, although the 
proportion of each is still a matter of debate2.The 
most abundant individual protein is from the renal 
tubules, Tamm-Horsfall protein. Other proteins 
include albumin, thyroxine-binding prealbumin, 
immunoglobulins, 1-antitrypsin, transferrin, 
-lipoprotein and low-molecular weight proteins1.
CAUSES OF PROTEINURIA
Proteinuria screening in pregnancy is focused on 
the detection of pre-eclampsia, the most common 
cause of proteinuria in pregnancy. Pre-eclampsia 
affects the glomeruli, and the lesion has been termed 
‘glomerular endotheliosis’. This terms describes 
glomerular endothelial swelling and loss of the 
integrity of the fenestrae (i.e., sieving apparatus), 
leading to leakage of protein into the renal tubules 
and associated occlusion of the capillary lumens3.
Proteinuria may be transient in pregnancy, 
although when identified, repeat testing must be 
SYNOPSIS
In pregnancy, there is a focus on measurement of proteinuria as it has been regarded as 
critical to the diagnosis of pre-eclampsia, the most dangerous of the hypertensive 
disorders of pregnancy. However, it is increasingly recognised that proteinuria is not 
essential for the diagnosis of pre-eclampsia, which can be based on other end-organ 
complications (such as elevated liver enzymes). Although heavy proteinuria has been 
linked with an increased risk of stillbirth in a ‘signs and symptoms only’ model of 
maternal risk (i.e., miniPIERS), we lack the ability to identify a level of proteinuria 
above which maternal and/or perinatal risk is heightened. Therefore, at present, we 
rely on the detection of proteinuria that exceeds what is normally excreted by healthy 
pregnant women. Proteinuria detection methods are also a matter of keen debate, with 
all available methods having advantages and disadvantages.
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done within days to ensure that pre-eclampsia is not 
missed and allowed to evolve unobserved. Transient 
causes are associated with normal renal function 
and no abnormalities of urinary sediment. Causes 
include orthostasis (i.e., upright posture), exercise, 
fever or sepsis, congestive cardiac disease, or central 
nervous system causes such as subarachnoid or 
intracerebral haemorrhage, or seizures. It should be 
noted that orthostatic proteinuria occurs in no 
more than 5% of adolescents and decreases in 
frequency with age, being less common in those 30 
years of age or older4.
When considering the causes of persistent 
proteinuria in pregnancy, a full differential diagnosis 
should be considered. How often new proteinuria 
is due to causes other than pre-eclampsia is unclear, 
especially in under-resourced settings. In the face 
of this uncertainty about the cause of the proteinuria, 
pre-eclampsia should be regarded as the working 
diagnosis given the maternal and fetal risks 
associated with this condition. Persistent proteinuria 
in pregnancy may be also caused by 
non-pre-eclampsia glomerular disease, tubular 
disease, or even non-renal disease (Table 2.1). 
Nephrotic-range proteinuria (3 g/d) is suggestive 
of glomerular renal disease. Abnormalities of the 
urinary sediment (e.g., micro- or macroscopic 
haematuria with IgA nephropathy) may or may not 
be seen with renal causes of proteinuria.
SCREENING FOR PROTEINURIA IN 
ANTENATAL CARE
At minimum, all pregnant women should be assessed 
for proteinuria in early pregnancy, to detect 
pre-existing renal disease and to obtain a baseline 
measurement in women at increased risk of 
pre-eclampsia7. Thereafter, most assessment for 
proteinuria occurs in women suspected of having 
pre-eclampsia, such as when women present with 
hypertension or suggestive symptoms (such as 
headache). The frequency of such screening is 
uncertain. Ideally, countries should move toward 
universal screening at every visit as pre-eclampsia/
eclampsia may first present with isolated proteinuria8. 
In the meantime, it would seem reasonable to retest 
for proteinuria in response to a rising blood pressure 
and/or maternal symptoms or maternal/fetal signs of 
Table 2.1 Causes of proteinuria (modified from Côté 
and Sauve67)
Transient causes
Orthostatic (i.e., related to upright posture)
Systemic (e.g., exercise, fever or sepsis, congestive cardiac 
disease)
Central nervous system (e.g., subarachnoic or intracerebral 
haemorrhage, seizures)
Contamination (e.g., from vaginal bleeding)
Persistent
Glomerular diseases
Pre-eclampsia
Pre-gestational diabetes type 1 or type 2
Immunoglobulin A (IgA) GN
Focal and segmental glomerulosclerosis (FSGS)
Lupus nephritis
Infection-related GN (e.g., HIV, hepatitis B and C, 
post-streptococcal, visceral abcess, endocarditis, other)
Drug-related GN
Other glomerular disease in young women: minimal 
change, membranous GN, membranoproliferative GN, 
other rare glomerular disease (e.g., amyloidosis), Fabry, 
Alport)
Non-glomerular (tubulointerstitial) disease
Structural (e.g., congenital anomalies, reflux nephropathy)
Polycystic kidney disease
Interstitial nephritis
Urinary tract infection 
GN, glomerulonephritis
POLICY IMPLICATION
Detecting proteinuria
• Proteinuria screening must be available 
wherever antenatal or postnatal care is 
provided
• At minimum, proteinuria testing must be 
performed at the first of the four 
WHO-recommended antenatal visits and 
whenever hypertension is detected5
• Proteinuria testing must be performed at the 
6-week postpartum visit in women who 
developed proteinuria in pregnancy6
(See Appendix 2.1)
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pre-eclampsia. It must be emphasised that proteinuria 
is but one diagnostic criterion for pre-eclampsia, and 
the end-organ complications of pre-eclampsia may 
occur in the absence of proteinuria. For example, in 
the latest eclampsia survey in the UK, 7.5% of 
women had only proteinuria (and 45% had neither 
hypertension nor proteinuria) in the week before 
their eclamptic seizure9.
As per the WHO postnatal recommendations 
for the care of the mother and newborn6, proteinuria 
should be re-tested in women who were identified 
as having had proteinuria in pregnancy, (see 
Chapter 11 for more information about postpartum 
management.)
MEASUREMENT OF PROTEINURIA FOR 
THE DIAGNOSIS OF PRE-ECLAMPSIA
There are many options for diagnosis of proteinuria, 
on either random (spot) samples (such as urinary 
dipstick testing, heat coagulation test, urinary 
protein : creatinine ratio (PrCr), or urinary 
albumin : creatinine ratio (ACR)) and various timed 
urine collections (usually 24-hour). Each has 
advantages and disadvantages and different results 
for diagnostic test accuracy (Appendix 2.2).
Urine tested for proteinuria should be as ‘fresh’ 
as possible. The longer the collection to testing 
interval, the more likely that bacterial contamination 
will skew the results. Without refrigeration, urine 
should be tested as soon as possible after collection, 
and definitely within 4 hours of collection. Urine 
collected over a 24-hour period must be refrigerated 
and brought to the laboratory on the day that 
collection finishes.
Point-of-care urine test strips come in opaque 
containers that specify expiry dates. They should 
not be used after that time. Once the container has 
been opened, the lid should be replaced between 
strip removal so that the unused strips are kept out 
of sunlight.
Urinary dipstick testing for proteinuria
There are many available types of urinary dipstick 
testing strips for visual and automated testing, and 
analysers for automated dipstick analysis. As it is 
unclear whether a particular method has an impact 
on test accuracy and pregnancy outcome, it may be 
prudent if possible, for the health care provider to 
use the same type of urinary dipsticks in the clinic 
and to send an individual patient to the same 
laboratory throughout her pregnancy so that 
differences in test results over time are more likely 
to be meaningful.
Visual interpretation of urinary dipstick
Urinary dipsticks may have up to 10 chemical pads 
for measuring different substances in urine, 
including protein and albumin, although strips that 
restrict measurement to proteinuria or albuminuria 
are available. The advantage of a strip with multiple 
pads is that it can reveal associated urinary 
abnormalities that are causes of low-level 
proteinuria, such as haematuria or either 
asymptomatic bacteriuria or symptomatic urinary 
tract infection (both of which should be treated 
with antibiotics) by showing leukocytes and nitrites. 
The disadvantages include multiple results that may 
result in confusion and inappropriate further 
investigation; for example, leukocytes may be a 
completely normal finding in pregnancy given 
contamination of the urine by vaginal discharge.
The urinary dipstick strip should be immersed 
completely in a well-mixed sample of urine for a 
short period of time, then extracted from the 
container and the excess urine removed by either 
supporting the edge of the strip over the mouth of 
the container, or drying the edges of the strip on 
absorbent paper (Figure 2.1). The strip is then left 
to stand for the time necessary for the reaction to 
occur (usually 60 seconds, as specified by the strip 
manufacturer). For visual analysis, the colour on 
the ‘proteinuria’ pad is compared with the 
chromatic scale specific to that strip and provided 
by the manufacturer. For automated analyses, the 
machine will read out the result. Results are 
reported as negative, trace, 1+, 2+, 3+, or 4+ based 
on the concentration of proteinuria detected. 
Although the concentration for a given ‘+’ may 
vary from one manufacturer to another (particularly 
at the 4+ stage), 1+ proteinuria usually reflects 
0.3 g/L of proteinuria. It follows that dehydration 
POLICY IMPLICATION
How to screen for proteinuria
Proteinuria screening should be performed 
using urinary dipsticks given their ease of use 
and low cost, until such time that another 
method proves to be superior
(See Appendix 2.1)
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can increase proteinuria concentration and result in 
a ‘positive’ proteinuria dipstick result.
Urinary dipstick testing for proteinuria is 
inexpensive, easy and widely used. In a systematic 
review, 1+ proteinuria by visual dipstick testing 
showed low sensitivity (55%, 95% CI 37–72) and 
reasonable specificity (84%, 95% CI 57–95) for 
detection of 0.3 g/d of proteinuria10. A threshold of 
2+ proteinuria by visual dipstick testing has 
reported sensitivity and specificity that varies from 
values of 58% 11 to values of 80%12–14. How should 
these results be interpreted for clinical practice? 
Given the <90% sensitivity of dipsticks using a 
threshold of 1+, a negative or trace value should 
not be ignored in a woman with new hypertension 
or symptoms or signs suggestive of pre-eclampsia. 
Given the reasonable specificity of dipsticks (at 1+ 
or 2+ levels), a result 1+ should prompt additional 
investigations even when the suspicion of 
pre-eclampsia is low. A urinary dipstick result of 
2+ is suggestive of 0.3 g/d or more of proteinuria 
by 24-hour urine collection.
Automated testing of urinary dipstick
In theory, automation has the potential to reduce 
errors arising from subjective interpretation of 
dipstick readings.
Comparisons of automated with visual-read 
dipsticks have used thresholds of either 1+ or 2+. 
Two studies have compared the diagnostic test 
properties of automated dipsticks for proteinuria 
with visual read urinary test strips for proteinur ia13,15, 
using a threshold of 1+. Although one study 
compared test strips with 24-hour urinary protein 
excretion (g/d)15 and the other study used 24-hour 
urinary protein concentration (g/L) as the 
comparator13, both studies demonstrated superior 
diagnostic test properties of automated (versus 
visual) testing, using a threshold of 1+ for 
proteinuria. In contrast, a more recent study failed 
to show superiority of automated over visual 
testing16. When a threshold of 2+ proteinuria was 
used, automated testing also appeared to be superior 
to visual testing13, with absolute values for sensitivity 
by automated testing as high as > 80%13,14 but as low 
as 23% in another study17.
For detection of proteinuria by 24-hour urine 
collection or PrCr, published sensitivities for an 
automated dipstick threshold of 1+ or more (41%17, 
82%15, 90%13 and 100%18) and corresponding 
specificities (100%, 81%, 86% and 37%) have varied 
widely, even when the prevalence of proteinuria in 
the study populations was similar (i.e., 45%15 and 
48%17).
The diagnostic accuracy of automated testing 
may depend on the choice of test strip and/or 
analyser. It may be premature to recommend 
widespread adoption of automated urine proteinuria 
test strip readers, although one international 
guideline makes such a recommendation19.
Urinary dipstick test strips are also available for 
detection of albuminuria (i.e., albumin 
concentration) specifically. However, we are not 
aware of studies that have compared albuminuria 
dipstick testing with proteinuria dipstick testing or 
other methods of proteinuria testing for detection 
of significant proteinuria in pregnancy. Of note, 
albuminuria dipsticks are more expensive than are 
proteinuria dipsticks.
HEAT COAGULATION TEST
The heat coagulation test may be used in 
under-resourced settings as an alternative to dipstick 
testing or other methods (discussed below) that are 
unavailable or too costly. A test tube is filled to 
two-thirds with urine. A few drops of dilute acetic 
acid are added to make the urine sample acidic. 
The upper part of the test tube containing urine is 
heated (but not boiled) over a burner.
The presence of protein is signified by the 
turbidity of the urine when the tube is placed in 
front of a typed sheet of paper according to a 
pre-specified chart (Figur e 2.2)20,21. The lower part 
of the tube of urine acts as a control as that urine 
should remain clear (Figure 2.3).
The heat coagulation test may be less sensitive 
than visually interpreted urinary dipsticks (at 1+ 
level) for detecting 0.3 g/d or more of urinary 
Figure 2.1 Accredited social health associate (ASHA) 
worker, India, performing urinary dipstick testing
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protein, however, it has reported specificity that is 
more tha n 90%20,21.
Sulfosalicylic acid testing
The sulfosalicylic acid (SSA) test is an alternative 
method of proteinuria testing for under-resourced 
settings. Ideally, the pH of urine is tested, and if >6, 
urine is acidified by adding one or two drops of 
10% acetic acid. Then, 2 mL of 3% sulfosalicylic 
acid is added. After shaking the test tube, the 
turbidity is observed (Figure 2.4) and the tube is 
placed in front of a black line or bold printed fonts. 
The turbidity of the urine (as inferred by the ability 
Figure 2.2 Performing the heat coagulation test and interpreting its results
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to see the black line or printed fonts) is used to infer 
the presence of proteinuria, as follows: (1) ‘negative’ 
when the black line or text is perfectly visible 
behind the first tube; (2) ‘weakly positive’ (protein 
concentration <0.3 g/L) when the black line or 
text is less visible; (3) ‘positive’ (protein 
concentration 0.3–1.0 g/L) when the black line or 
text is not quite visible; and (4) ‘strongly positive’ 
(protein concentration >1.0 g/L) when the black 
line or text is not visible at all22.
Interest in using proteinuria testing by SSA as a 
screening test for proteinuria was based on the test’s 
low cost, good specificity, feasibility and reliability. 
In the 1980s, WHO recommended SSA testing for 
use in primary care centres, and two studies 
evaluated its test performance. Sensitivity and 
specificity of proteinuria testing in the field by SSA 
were 94.4% and 96.7% compared with dipstick 
testing (interpretation by laboratory staff presumed 
to be visual)22, and 41.1% and 97.7%, respectively, 
compared with 24-hour urinary protein23. There 
are no published direct comparisons of the heat 
coagulation test and SSA. However, given that SSA 
testing is easier to perform and has similar diagnostic 
properties (when testing is compared with 24-hour 
urine testing), SSA testing would seem preferable.
Spot protein : creatinine ratio
Although point-of-care testing for spot PrCr is 
emerging and PrCr is easily collected by women, all 
PrCr ratio studies in pregnancy have had 
measurement of the protein and creatinine 
concentrations in a random urine sample performed 
then results calculated in the laboratory (Figure 
2.5). There are many assays for proteinuria and 
creatinine; poor reporting of laboratory methods 
has prevented an analysis of the impact of various 
assays on PrCr results. Rapid interpretation has 
been further complicated by reporting of PrCr 
results in various units. Nevertheless, the urinary 
PrCr ratio has been accepted for diagnosis of 
proteinuria by the International, American, 
Australasian, Canadian and British pregnancy 
hypertension societies. In a systematic review, the 
reported cut-off varied from 17 to 57 mg/mmol 
(0.15–0.50 mg/mg) (median 24 mg/mmol) in nine 
studies (1003 hypertensive women). For a cut-off 
Figure 2.3 Heat coagulation test tube showing 
proteinuria as turbidity at the top of the tube
Figure 2.4 Turbidity of the urine after addition of acetic acid as part of sulfosalicylic acid (SSA) testing (from http://
www.eclinpath.com/urinalysis/chemical-constituents/urine-protein-ssa/)
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of 30 mg of protein/mmol urinary creatinine, and 
among women with a hypertensive disorder of 
pregnancy specifically, the sensitivities and 
specificities were 83.6% (95% CI 77.5–89.7) and 
76.3% (95% CI 72.6–80.0), respectively24. A more 
recent systematic review suggests that the optimum 
threshold for PrCr ratio to detect significant 
proteinuria may actually be slightly higher, at 
34–40 mg/mmol (0.30–0.35 mg/mg) (summary 
sensitivity and specificity both >75% for 15 studies, 
2790 women), although no threshold gave a 
sensitivity and specificit y >80%25. A further 
meta-analysis of 24 studies (3186 women) 
endorsed a cut-off of 34 mg/mmol (0.30 mg/mg), 
with sensitivity and specificity >80%26. Four 
additional studies individually found sensitivity and 
specificities of at least 80% with optimal cut-offs of 
27 mg/mmol (0.24 mg/mg)27, 30 mg/mmol28, 
51 mg/mmol (0.45 mg/mg)11, and 53 mg/mmol 
(0.47 mg/mg)29, consistent with the previously 
reported range of 17–57 mg/mmol. One additional 
report was just outside this range (71 mg/mmol, 
0.63 mg/mg)30, and three others found that optimal 
cut-offs did not have both sensitivity and specific ity 
80%31–33. Taken together, we feel that continued 
use of the threshold of 30 mg/mmol is reasonable, 
but do recommend that proteinuria testing be 
viewed as only one aspect of the investigation of 
women with a hypertensive disorder of pregnancy 
and interpreted in the context of clinical symptoms, 
signs and other laboratory testing. A higher 
threshold may be more appropriate in twin 
 pregnancy34,35.
The best timing of spot urine sampling is 
debated. However, timing may not be critical in 
pregnancy36–38 which is ideal for women with 
suspected pre-eclampsia who can be tested for 
proteinuria at the time of clinical presentation.
Spot albumin : creatinine ratio
Most clinical laboratories use immunoassays to 
measure urinary albumin, so there is less theoretical 
inter-laboratory variability for albuminuria than 
for proteinuria. (The remainder of labs use 
colourimetric methods that are less precise for 
low-level albuminuria.) However, there is no 
standardisation of method, and there are also 
multiple methods for measuring urinary creatinine, 
as stated for the PrCr. The impact of laboratory 
assays on albumin : creatinine ratio (ACR) results is 
not known.
Urinary ACR testing is available by a variety of 
point-of-care dipsticks. Three studies have 
evaluated performance in pregnancy. Two studies 
found the automated-read ACR dipstick to be 
insensitive: one used the ACR performed on a spot 
sample sent to the laboratory as the reference test 
using a cut-off of 3.4 mg/mmol (65 low risk and 43 
high risk pregnancy cases)39. The second used 
24-hour urinary protein as the reference test; 
reported sensitivity and specificity were 63% and 
81%, respectively (163 hypertensive women)40. 
The third evaluated both visual and automated 
ACR dipstick performed at the bedside compared 
with 24-hour urinary protein (171 hypertensive 
women); automated ACR dipstick fared only 
slightly better than visual ACR dipstick with 
regards to sensitivity (i.e., 58% vs. 49%, respectively) 
and specificities were 83% for both approaches; 
neither ACR dipstick (visual or automated-read) in 
that study was better than visual proteinuria dipstick 
testing (which had a sensitivity of 51% and a 
specificity of 78%) for detection of 0.3 g/d or more 
of urinary protein in 24-hour collection15.
Urinary ACR testing on spot urine samples is 
widely available in clinical laboratories in 
well-resourced settings. Most, but not all, studies 
have reported good test performance. The urinary 
ACR has performed well in: (1) detection of 
24-hour urinary protein excretion in four 
prospecti ve studies18,41–43 (410 pregnant  women), 
and (2) detection of 24-hour urinary albumin 
excretion in two ot her studies44,45 (119 pregnant 
Figure 2.5 Woman in Nigeria preparing to collect her 
spot urine sample for protein : creatinine ration (PrCr) 
testing
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women). An additional study reported that ACR 
correlated well with 24-hour albuminuria but not 
with 24-hour proteinuria46 (31 women diagnosed 
with pre-eclampsia). Moreover, three different 
diagnostic cut-offs (of 2, 8 and 22.8 mg/mmol, 
equivalent to 18, 71 and 205 mg/g) have been 
reported for significan t proteinuria15,18.
In summary, there is insufficient information 
about use of ACR testing (by dipstick or through 
the laboratory) in pregnancy to recommend their 
use at the present time.
Timed urine collection
Quantification of urinary protein by 24-hour 
urine collection is considered to be the gold 
standard. However, 24-hour urine collection is 
time-consuming, inconvenient and often inaccurate 
due to inadequate 24-hour urine collection (as 
assessed by urinary creatinine collection of 13–18% 
of pre-pregnancy body weight as urinary creatinine 
(mmol/d))47. For diagnosis of proteinuria in 
non-pregnant populations, these logistical 
considerations have prompted the National Kidney 
Foundation and the International Society of 
Nephrology to abandon timed collections in 
favour of the spot urine samples48,49. However, if 
quantification of proteinuria is sought, then 
24-hour urine collection for protein and creatinine 
should be used at high levels of proteinuria (i.e., 
spot PrCr >125 mg/mmol which is roughly 
equivalent to more than 1 g/d of proteinuria by 
24-hour urine collection) as the spot PrCr is less 
reliable at high levels of proteinuria.
WHAT CONSTITUTES ‘SIGNIFICANT’ 
PROTEINURIA IN PREGNANCY?
Although 0.3 g/d of proteinuria represents the 
upper 95% confidence interval for proteinuria 
excretion in pregnancy, this threshold does not 
necessarily identify women at increased risk of 
adverse maternal and/or fetal outcomes. That 
threshold is not known.
A recent study reported that women who had 
0.5 g/d were at higher risk of adverse outcomes 
than those wi th 0.3–0.5 g/d50. (This is discussed 
further in Chapter 3.)
In well-resourced settings where full maternal 
and fetal assessment is available, the magnitude of 
proteinuria once identified is not related to either 
short-term adverse maternal or perinatal outcomes, 
or long-term maternal renal prognosis. In the 
fullPIERS cohort, a prospective study of women 
admitted to hospital with pre-eclampsia, the 
magnitude of proteinuria (by 24-hour urine 
collection, visual dipstick testing, or spot PrCr) was 
not associated with adverse maternal or perinatal 
outcomes independent of routinely collected 
information on maternal symptoms, signs and b asic 
blood work51 (see Chapter 3). At least one 
observational study of women with pre-eclampsia 
failed to identify a definition of heavy proteinuria 
that was associated with adverse renal prognosis52.
In contrast, in resource-poor settings where 
maternal symptoms and signs alone are used to 
guide treatment, proteinuria of 4+ is associated 
with an increased r isk of stillbirth53.
COST CONSIDERATIONS
Although visual dipstick proteinuria testing is the 
most widely used of the screening methods, there is 
no cost-effectiveness analysis of its use followed by 
confirmatory testing (with PrCr or 24-hour urine 
collection) for values 1+ or 2+.
The only health economic analyses identified 
were those conducted by the NICE Clinical 
Guideline Committee, for women with gestational 
hypertension who live in settings where all tests are 
available54. The Committee considered both the 
convenience of testing for health care providers 
and women, and the trade-off between the costs of 
a false positive test for proteinuria and the costs of 
missed adverse pregnancy outcomes. The analyses 
were highly influenced by the sensitivity of 
proteinuria testing methods. Assuming that 
sensitivity is high for both the automated dipstick 
and spot PrCr methods, spot PrCr may be more 
cost-effective than a strategy of automated dipstick 
testing followed by confirmation of 1+ proteinuria 
by either spot PrCr or 24-hour urine collection.
In low-resource referral hospital settings, 
limitations in central laboratory facilities will affect 
cost-benefit considerations.
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PRIORITIES FOR UNDER-RESOURCED 
SETTINGS
Proteinuria testing is recognised by WHO to be as 
a marker of high quality antenatal care55. In fact, 
proteinuria testing was recommended along with 
blood pressure monitoring as the original rationale 
for antenatal care. As such, implementation of 
proteinuria screening in low- and middle-income 
countries (LMICs) is a priority.
Demographic health survey data (2002–2008) 
indicate that few LMICs exceed a standard of urine 
testing in more than 80% of women attending 
antenatal care. The rate of urine testing at routine 
antenatal care visits is highly variable56, particularly 
in sub-Saharan Africa and South/Southeast Asia 
where urine testing rates vary from testing in only 
25% of women to testing in close to 100%. Urine 
testing occurs in at least 50% of women in North 
Africa/West Asia/Europe and at least 67% of 
women in Latin American/Caribbean countries. 
These data indicate a major failure of basic health 
system provision that inevitably results in avoidable 
large scale morbidity and mortality from 
hypertensive disease in pregnancy.
Table 2.2 outlines the priorities for 
implementation of proteinuria testing in LMICs, 
depending on the timing of testing (in pregnancy 
and postpartum) and the level of the health care 
system. In brief, the first priority is detection 
of women with pre-eclampsia (by testing for 
proteinuria at 20 weeks of pregnancy and beyond), 
followed by detection of women with underlying 
renal disease (by testing in the first or early second 
trimester, and at 6 weeks postpartum among 
women with proteinuria in pregnancy) who are at 
increased risk of pre-eclampsia.
Innovative proteinuria measurement devices are 
on the horizon for use in under-resourced settings 
and it is hoped that they will facilitate 
implementation of the priorities for testing outlined 
in Table 2.2. While the priority in high-income 
settings is towards laboratory-based analyses, the 
focus in LMICs is on point-of-care testing, 
particularly by community health care providers. 
Three active research tracks are as follows:
• The proteinuria self-test for early detection of 
pre-eclampsia (the ‘proteinuria pen’) was designed 
by graduate students at John Hopkins University, 
BEST PRACTICE POINTS
(Please see Appendix 2.3 for the evaluation of the strength of the recommendation and the quality of the 
evidence on which they are based.)
1. All pregnant women should be assessed for proteinuria, at minimum, at their first antenatal visit.
2. Urinary dipstick testing (or SSA or heat coagulation testing if dipsticks are not available) may be used 
for screening for proteinuria when the suspicion of pre-eclampsia is low.
3. Significant proteinuria should be strongly suspected when urinary dipstick proteinuria is 2+.
4. Definitive testing for proteinuria (by urinary protein : creatinine ratio or 24-hour urine collection) is 
encouraged when there is a suspicion of pre-eclampsia.
5. Significant proteinuria is 0.3 g/d in a complete 24-hour urine collection or 30 mg/mmol (0.3 mg/
mg) urinary creatinine in a random urine sample.
6. There is insufficient information to make a recommendation about the accuracy of the urinary 
albumin : creatinine ratio, although values <2 mg/mmol (<18 mg/g) are normal and all values 
8 mg/mmol (71 mg/g) are elevated.
7. In well-resourced settings with sophisticated fetal monitoring, proteinuria testing does not need to 
be repeated once the significant proteinuria of pre-eclampsia has been confirmed.
8. In under-resourced settings, proteinuria testing should be repeated to detect 4+ dipstick proteinuria 
that is associated with an increased risk of stillbirth.
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USA (http://www.appropedia.org/Proteinuria_
Self-Test_Pen). Field testing is currently under 
the management of Jhpeigo. This felt-tip or 
ballpoint pen is filled with reagent that is used to 
mark a strip of paper. When a drop of urine is 
placed on the paper, if there is proteinuria, the 
reagent changes colour. The test is anticipated to 
cost <US$0.10 per use. 
• Point-of-care paper-based microfluidic diagnostic 
‘stamps’ have been developed by Diagnostics for 
All. Paper and an office printer are the equipment 
required to generate the postage stamp-sized 
paper testing tool, onto which a reagent and 
drop of urine are applied to indicate proteinuria 
( h t t p : / / w w w. s a v i n g l i v e s a t b i r t h . n e t /
summaries/60). The test is anticipated to cost 
<US$0.10 per use).
• The urinary Congo red dot test uses a textile 
dye to detect elevated concentrations of 
misfolded urinary protein associated 
with pre-eclampsia57 (http://www.usaid.gov/
n e w s - i n f o r m a t i o n / f r o n t l i n e s /
open-development-development-defense/
pinpointing-preeclampsia-simple-red).Testing 
requires the user to mix dye and urine together 
and put a drop on a piece of paper, where dye 
and any misfolded proteins in the urine 
combined to form a ‘red dot’57. The test is 
anticipated to cost pennies per use.
WHAT INTERNATIONAL GUIDELINES 
SAY (APPENDIX 2.4)
Abbreviations for Clinical Practice Guidelines: 
ACOG (American College of Obstetricians and 
Gynecologists)58, AOM (Association of Ontario 
Midwives), NICE (National Institutes of Clinical 
Excellence)59, NVOG (National Obstetrics and 
Gynaecology Society, Netherlands)60, PRECOG 
(Pre-eclampsia Community Guideline), PRECOG 
II (Pre-eclampsia Community Guideline II), QLD 
(Queensland, Australia)61, SOGC (Society of 
Obstetricians and Gynaecologists of Canada)62, 
SOMANZ (Society of Obstetric Medicine of 
Australia and New Zealand)63, WHO (World 
Health Organization)64.
Screening for proteinuria is advocated by five 
clinical practice guidelines for women with a 
hypertensive disorder of pregnancy (AOM65, NICE, 
PRECOG66, SOGC, SOMANZ); when performed, 
Table 2.2 Prioritisation of urine testing for proteinuria by timing and level of health care system at which testing occurs
Antepartum Postpartum
Initial priority Ultimate goal Initial priority Ultimate goal
Community
Primary health 
care centre
(detect and 
refer)
Urinary (clean-catch) 
dipstick testing at 
each visit after 20 
weeks to detect 
pre-eclampsia
Urinary (clean-catch) 
dipstick testing at 
booking and at each 
visit after 20 weeks to 
detect both chronic 
renal disease and 
pre-eclampsia
Urinary (clean-catch) dipstick 
testing within 24 hours of 
delivery in hypertensive women 
to detect postpartum 
pre-eclampsia
Urinary (clean-catch) 
dipstick testing at 6 
weeks after delivery for 
women with antenatal 
proteinuria to detect 
underlying renal disease 
and prompt referral
Facility
Secondary-level 
facility
(detect and 
manage/refer)
Urinary (clean-catch) 
dipstick testing at 
booking and at each 
visit after 20 weeks 
to detect both 
chronic renal disease 
and pre-eclampsia
Availability of 
confirmatory test for 
proteinuria in women 
with 1+ by urinary 
dipstick testing
Postpartum urinary (clean-catch) 
dipstick testing within 24 hours 
of delivery in hypertensive 
women to detect postpartum 
pre-eclampsia
Postpartum urinary (clean-catch) 
dipstick testing at 6 weeks after 
delivery for women with 
antenatal proteinuria to detect 
underlying renal disease and 
prompt referral
Tertiary-level 
(referral) facility
(detect and 
manage)
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testing methods should be by dipstick (visual) 
(PRECOG, AOM), automated (NICE), or either 
(SOGC), but NICE advocates using a random urine 
protein:creatinine ratio (PrCr) in a secondary care 
setting. Significant thresholds for proteinuria are: 
1+ (PRECOG, SOGC) or 2+ (PRECOG II68, 
QLD), with two guidelines specifying that a 
threshold of 1+ should be used only when there is 
associated hypertension (PRECOG II) or other 
manifestations of pre-eclampsia (AOM).
For quantification of proteinuria, criteria are: 
‘dipstick’ 1+ (AOM), random urine PrCr 
30 mg/mmol (PRECOG, PRECOG II, NICE, 
SOGC), and/or 24-hour urinary protein 0.3 g/d 
(PRECOG, PRECOG II, NICE, NVOG, ACOG 
SOGC) (with completeness of the urine collection 
emphasised by two CPGs (NICE, SOGC)).
PRIORITIES FOR FUTURE RESEARCH
• In low-resource country service settings, health 
systems research is needed on how to ensure 
consistent proteinuria screening in antenatal 
care, to the levels that are now being achieved 
for HIV testing.
• By current testing methods, what is the level of 
proteinuria that identifies a woman and/or fetus 
at increased risk of an adverse outcome?
• Are there better ways of measuring 
proteinuria? These should be cheaper and related 
to the risk of adverse pregnancy outcome. Three 
simple approaches, all point of care, show 
promise.
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